Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2015

01-03-2015 | Original Paper

CD40 expression and its prognostic significance in human gastric carcinoma

Authors: Jing Guo, Jia-Jia Xiao, Xiaoli Zhang, Kai-Xi Fan

Published in: Medical Oncology | Issue 3/2015

Login to get access

Abstract

This study aimed to detect the relationship between CD40 (protein and mRNA) expression and human gastric cancer and to determine the prognostic significance of CD40 in gastric cancer patients. We collected 128 cases of gastric cancer specimens, and the expression of CD40 (protein and mRNA) was measured by immunohistochemistry and in situ hybridization. Our study indicated that CD40 is constitutively expressed in human gastric carcinoma tissues. Positive expression of CD40 (protein and mRNA) in gastric cancer tissues was closely related to the tumor TNM stage and the presence of distant metastasis, with CD40 mRNA also being correlated with the presence of lymphatic metastasis. Furthermore, the expression of CD40 (protein and mRNA) is closely related to the prognosis of gastric cancer patients. The expression of CD40 protein and mRNA is positively correlated with the presence of distant (for both protein and mRNA) and lymphatic (for mRNA only) metastasis, and an increased tumor TNM stage in gastric carcinoma. Patients who express low levels of CD40 may have a better prognosis than those who have higher levels of CD40.
Literature
1.
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer. 2008;127:2893–917.CrossRef
3.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
4.
Vestal RE, Wingett LK, Kinght LK, et al. Expression of CD40 in breast, colon, lung and ovarian tumors. Proc Am Assoc Cancer Res. 1997;38:A1550–6.
5.
Van Kooten C, Bancherean J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330–41.CrossRefPubMed
6.
Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40–CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000;37:515–26.CrossRefPubMed
7.
8.
9.
10.
Furman RR, Forero-Torres A, Shustov A, et al. A phase I study of dacetuzumab(SGN-40, a humanized anti-CIM0 monoclonal antibody)in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;. doi:10.​3109/​1042819090344094​6.PubMed
11.
Lo SS, Wu CW, Chi CW, Li AF, Chen JH, Lui WY. High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis. Hepatogastroenterology. 2005;52(66):1902–4.PubMed
12.
13.
Bosman F, Cameiro F, Hmban R, editors. WHO classification of tumours of the digestive system. Lyon: iarc Press; 2010.
14.
Leslie HS, Mary KG, Christian W, editors. TNM classification of malignant tumors. 7th ed. New York: John Wiley & Sons Inc; 2009.
15.
Zhang BH, Liu W, Li L, Lu JG, Sun YN, Jin DJ, Xu XY. KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2013;14(6):3521–6.CrossRefPubMed
16.
17.
Yamaguchi H, Tanka F, Sadanaga N, et al. Stimulation of CD40 inhibits Fas-or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol. 2003;23:1697–702.PubMed
18.
Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003;278:18008–14.CrossRefPubMed
19.
20.
Brian G, Werneburg G, Stephen J, et al. Molecular charaterization of CD40 signaling intermediates. J Biol Chem. 2001;46:43334–42.
21.
Ottaiano A, Pisano C, De Chiara A, et al. CD40 activation as potential tool in malignant neoplasms. Tumori. 2002;88:361–6.PubMed
22.
Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4(4):360–7.CrossRefPubMed
23.
Lee HH, Dadgostart H, Cheng Q, Shu J, Cheng G. NK-jB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signalling in B lymphocytes. Proc Natl Acad Sci USA. 1999;96:9136–41.PubMedCentralCrossRefPubMed
24.
Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med. 2001;193:447–58.PubMedCentralCrossRefPubMed
25.
26.
Byrd JC, Kipps TJ, Flinn IW, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab(HCDl22)in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012;. doi:10.​3109/​10428194.​2012.​681655.
27.
Vonderheide RH, Flaheny KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP·870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–83.CrossRefPubMed
Metadata
Title
CD40 expression and its prognostic significance in human gastric carcinoma
Authors
Jing Guo
Jia-Jia Xiao
Xiaoli Zhang
Kai-Xi Fan
Publication date
01-03-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0463-0

Other articles of this Issue 3/2015

Medical Oncology 3/2015 Go to the issue

Erratum

Erratum to: Slug signaling is up-regulated by CCL21/CCR7 to induce EMT in human chondrosarcoma

Original Paper

Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study

Original Paper

Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes

Original Paper

Acoustic radiation force impulse elastography for differentiation of benign and malignant thyroid nodules with concurrent Hashimoto’s thyroiditis

Original Paper

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Review Article

Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits